RxDoctor Payments Data

Jennifer Nicholson

Adult Health · Greenville, SCNPI 1528473824

Payments from drug & device makers

$1,245in general payments, 2019–2025

Across 58 payments — averaging $21.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$431
  • AbbVie$270
  • Biomerieux Inc$185
  • Lilly USA, LLC$107
  • Vanda Pharmaceuticals Inc.$39
  • Xeris Pharmaceuticals, Inc.$35
  • plus $176 from 9 others

What the payments were for

  • Food & beverage$1,245100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,245 in reported general payments places this provider in the 55th percentile of 292 adult health providers in South Carolina.

See all adult health providers in South Carolina

Medicare billing

Part B allowed, 2024
$406,985
Medicare patients
64
Services billed
1,167

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide26$35,017
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$16,248
MounjaroTirzepatide12$12,515
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$11,172
EliquisApixaban12$5,773
Albuterol Sulfate HfaAlbuterol Sulfate45$1,047
Omeprazole57$945
Atorvastatin Calcium80$690
Levothyroxine Sodium45$547
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine15$535
Fluticasone Propionate38$511
Gabapentin31$420
Ramipril43$405
Carvedilol53$370
Amlodipine Besylate63$313

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$29$35,01726 claims
Lilly USA, LLCMounjaro$107$12,51512 claims
AstraZenecaBreztri Aerosphere$431$11,17214 claims
PfizerEliquis$27$5,77312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 292 adult health providers in South Carolina.

Other adult health in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →